Double-walled poly-(D,l-lactide-co-glycolide) (plga) and poly(l-lactide) (plla) nanoparticles for the sustained release of doxorubicin

M. Margarida Cardoso, Inês N. Peça, Telma Lopes, Rui Gardner, Ana Bicho

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
15 Downloads (Pure)


Double-walled nanoparticles (DWNPs), containing doxorubicin as a model drug, were produced using poly-(D,L-lactide-co-glycolide) (PLGA) and poly(L-lactide) (PLLA) by the solvent evaporation technique. Double-walled microparticles containing doxorubicin were also produced to make possible the examination of the inner morphology and drug distribution using optical and fluorescence microscopy. The produced microparticles present a double-walled structure with doxorubicin solubilized in the PLGA-rich phase. The DWNPs produced present very low initial burst values and a sustained DOX release for at least 90 days with release rates decreasing with the increase in the PLLA amount. Zero-order release kinetics were obtained after day 15. The results support that the PLLA layer acts as a rate control barrier and that the diffusion of doxorubicin from the drug-loaded inner PLGA core can be retarded by an increase in the thickness of the unloaded outer layer. The unloaded double-walled nanoparticles produced were used in in vitro tests with CHO cells and demonstrate that they are nontoxic, while the double-walled nanoparticles loaded with doxorubicin caused a great cellular viability and decreased when tested in vitro.

Original languageEnglish
Article number3230
Publication statusPublished - 23 Sept 2021


  • Controlled release
  • Double-walled nanoparticles
  • Doxorubicin
  • Drug delivery


Dive into the research topics of 'Double-walled poly-(D,l-lactide-co-glycolide) (plga) and poly(l-lactide) (plla) nanoparticles for the sustained release of doxorubicin'. Together they form a unique fingerprint.

Cite this